Standardized Bleeding Definitions for Cardiovascular Clinical Trials A Consensus Report From the Bleeding Academic Research Consortium
Standardized Bleeding Definitions for Cardiovascular Clinical Trials A Consensus Report From the Bleeding Academic Research Consortium
复制标题
DOI：
10.1161/circulationaha.110.009449
复制
发表时间：
2011-06-14
期刊：
影响因子：
37.8
通讯作者：
White, Harvey
中科院分区：
文献类型：
--
作者：
Mehran, Roxana;Rao, Sunil V.;White, Harvey
抗血栓治疗的进展，沿着早期侵入性策略，降低了急性冠状动脉综合征（ACS;不稳定型心绞痛、非ST段抬高型心肌梗死[MI]和ST段抬高型MI）患者复发性缺血事件和死亡的发生率。1-4然而，多种药物联合治疗，包括阿司匹林、血小板P2 Y12抑制剂、肝素加糖蛋白IIb/IIIa抑制剂、直接凝血酶抑制剂，以及侵入性操作的使用增加，也与出血风险增加相关。
Advances in antithrombotic therapy, along with an early invasive strategy, have reduced the incidence of recurrent ischemic events and death in patients with acute coronary syndromes (ACS; unstable angina, non–ST-segment–elevation myocardial infarction [MI], and ST-segment–elevation MI). 1–4 However, the combination of multiple pharmacotherapies, including aspirin, platelet P2Y12 inhibitors, heparin plus glycoprotein IIb/IIIa inhibitors, direct thrombin inhibitors, and the increasing use of invasive procedures, has also been associated with an increased risk of bleeding.